Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Phase III
St. Jude Children's Research Hospital Release: Experimental Breast Cancer Drug Holds Promise In Combination Therapy For Ewing Sarcoma 10/23/2014 11:25:54 AM
Derma Sciences, Inc. (DSCI) Presented Clinical Evidence And Data On Its Tissue Regeneration Products for Diabetic Foot Ulcers At Fall 2014 Symposium On Advanced Wound Care 10/23/2014 11:22:16 AM
Upsher-Smith Laboratories Presents New Data On The Administration Of Qudexy™ XR (Topiramate) Extended-Release Capsules Through Enteral Feeding Tubes 10/23/2014 9:21:53 AM
Alcobra (ADHD) Announces Presentation Of New Data From Phase 3 Adult ADHD Study At AACAP Annual Meeting 10/23/2014 7:31:08 AM
MorphoSys AG To Receive Milestone Payment For Guselkumab Phase 3 Program 10/23/2014 7:18:57 AM
Novartis AG (NVS)'s AIN457 Meets Primary Endpoint In Two Late Stage Studies 10/23/2014 5:35:41 AM
AcelRx Pharmaceuticals (ACRX)'s Zalviso Met Primary Endpoint In Phase 3 Study 10/22/2014 5:51:25 AM
Immune Pharmaceuticals, Inc. Release: New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease 10/22/2014 8:01:23 AM
Repros Therapeutics Inc. (RPRX) Release: Results From Long-Term Study Of Androxal® Exhibit Positive Safety Profile 10/22/2014 7:00:11 AM
Despite Conflicting Data, Cytokinetics, Inc. (CYTK) Plans To Take ALS Drug Into Late Stage Study 10/20/2014 11:21:03 AM
Salix Pharmaceuticals, Ltd. (SLXP)’s TARGET 3 Study Examines The Safety And Efficacy Of Repeat Treatment With Rifaximin 550 mg For Irritable Bowel Syndrome With Diarrhea 10/21/2014 11:09:20 AM
Boehringer Ingelheim Corporation Initiates Global Phase 3 Study Investigating Nintedanib In Patients With Colorectal Cancer 10/21/2014 7:17:00 AM
Neurocrine Biosciences, Inc. (NBIX) Announces Initiation Of Phase 3 Study For VMAT2 Inhibitor NBI-98854 10/21/2014 7:15:07 AM
Regeneron (REGN), Sanofi (SAN.PA) Begin Pivotal Phase 3 Study For Eczema Drug Dupilumab 10/20/2014 5:41:08 AM
Results From Two Phase 3 Studies Added To U.S. Label Of Genzyme’s Aubagio 10/20/2014 10:34:17 AM
1234567
//-->